Clinical trialNCT04763759CompletedPhase 1Interventional

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

SponsorTrellis Bioscience LLCEnrollment15Prosthetic Joint Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or preservation of the original infected prosthetic joint in a substantial proportion of patients with PJI.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Daniel Oakes, MD
University of Southern California
Principal Investigator
clinicaltrials.gov ↗
Edward Stolarski, MD
Gulfcoast Research Institute
Principal Investigator
clinicaltrials.gov ↗
Ian Duensing, MD
UVA
Principal Investigator
clinicaltrials.gov ↗
Janet Conway, MD
Sinai Hospital of Baltimore
Principal Investigator
clinicaltrials.gov ↗
Luis Pulido, MD
University of Florida
Principal Investigator
clinicaltrials.gov ↗
Nicholas Bernthal, MD
University of California, Los Angeles
Principal Investigator
clinicaltrials.gov ↗
Richard Berkowitz, MD
Phoenix Clinical Research
Principal Investigator
clinicaltrials.gov ↗
Sameer Naranje, MD
University of Alabama at Birmingham
Principal Investigator
clinicaltrials.gov ↗
Stephen Incavo, MD
The Methodist Hospital Research Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama
Birmingham, Alabama, United States
Usc
Los Angeles, California, United States
Ucla
Santa Monica, California, United States
University of Florida
Gainesville, Florida, United States
Gulfcoast Research Institute
Sarasota, Florida, United States
Phoenix Clinical Research
Tamarac, Florida, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Houston Methodist Research Institute
Houston, Texas, United States
University of Virginia
Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TRL1068, a human monoclonal antibody

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Feb 2021
Primary completion: 13 Mar 2024
Completion: 13 Mar 2024
Last update posted: 21 Nov 2024
Registered enrollment: 15
Registry id: NCT04763759

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.